Project Grant R01AI202116
Award Date 8/21/26
Completion Date 7/31/31
Dollars Obligated $650K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Newark, DE 19713, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Iowa $684,797 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the genetic requirements for lipoteichoic acid synthesis in Clostridioides difficile. The research addresses antibiotic resistance in C. difficile, the leading cause of hospital-acquired infectious diarrhea. Current treatment options...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded the University of Idaho $505,406 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cell form determination during the chlamydial intracellular infectious cycle. The award funds research into the mechanisms regulating distinct developmental cell forms—the reticulate body (RB),...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $427,625 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model the vaginal microbiome and predict bacterial vaginosis recurrence. The research applies metagenomic community state types to identify functionally distinct presentations of bacterial vaginosis and develop preventative interventions, addressing the high recurrence rates—60 percent at six...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $717,952 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate host lipid acquisition and the maintenance of the Chlamydia replicative niche. The research addresses Chlamydia trachomatis infection, the leading cause of bacterial sexually transmitted infections, for which no vaccine exists. The project will test the hypothesis that a single...
- The National Institute of Allergy and Infectious Diseases awarded Rowan University $193,750 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop pathogen-activated antimicrobial peptides for preventing catheter-associated urinary tract infections. The award funds the design, optimization, and validation of antimicrobial pro-peptides that remain inactive until cleaved by uropathogenic Escherichia coli–specific enzymes. This pathogen-selective...
- The National Institute of Allergy and Infectious Diseases awarded The Pennsylvania State University $113,853 on December 12, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate polymicrobial interactions in bile acid metabolism by the gut microbiome. The research decodes cross-species metabolic pathways through which gut bacteria convert host-derived primary bile acids into secondary bile acids, including 7a-dehydroxylated deoxycholic acid and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $146,920 on November 30, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the molecular mechanisms of bacterial multidrug efflux transporters and antimicrobial resistance. The funded research combines deep mutational scanning with in vivo and in vitro validation to characterize how the NorA efflux transporter exports structurally and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Arkansas for Medical Sciences $447,720 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and employ innovative in vitro and in vivo platforms for studying Acinetobacter baumannii ventilator-associated pneumonia (VAP) pathogenesis and prevention strategies. The research addresses a critical gap in VAP science: A. baumannii causes approximately 30 percent of...